Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of
ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.